Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022–2023 and 2023–2024 seasons - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Effectiveness of Adjuvanted and High-Dose Influenza Vaccines Against Confirmed Influenza Outcomes, Including Hospitalizations, in Older Adults During the 2022–2023 and 2023–2024 Seasons

  • By

  • Mahrukh Imran

  • Benjamin Chastek

  • Tim Bancroft

  • Noah Webb

  • Stephen I. Pelton

  • Mendel D.M. Haag

  • Ian McGovern

  • September 1, 2026

Share

  • 1

    Adults aged ≥65 years account for an estimated 70% to 85% of seasonal influenza-related deaths and 50% to 70% of influenza-related hospitalizations in recent years.

  • 2

    The WHO recommends annual influenza vaccination for people at high risk of complications, including adults aged ≥65 years.

  • 3

    Adjuvanted and high-dose influenza vaccines were developed to improve vaccine effectiveness in older adults, whose immune responses are diminished by immunosenescence.

  • 4

    The study evaluated the relative vaccine effectiveness of aQIV versus HD-QIV against test-confirmed influenza in adults aged ≥65 years during the 2023–2024 season.

  • 5

    Optum Market Clarity electronic health record and claims data were used to assess relative vaccine effectiveness against test-confirmed influenza and test-confirmed influenza hospitalizations.

Original Source(s)

Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022–2023 and 2023–2024 seasons

  • by Mahrukh Imran, Benjamin Chastek, Tim Bancroft, Noah Webb, Stephen I. Pelton, Mendel D.M. Haag, Ian McGovern

  • September 1, 2026

Related Content

Tea saponin–soybean oil submicron emulsion promotes durable protective immunity against Pasteurella multocida

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.

Response to: Methodological issues of paper about the 2025 measles outbreak in Mexico